DRUG · Mapped RxNorm record
Naloxegol
Normalized identity: naloxegolView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT03087708
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Laboratory Biomarker Analysis
Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Quality-of-Life Assessment
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedNaloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Stage IIIB Non-Small Cell Lung Cancerunresolved
Stage IV Non-small Cell Lung Cancerunresolved
Interventions
NaloxegolDRUG · verified · RxNorm: naloxegol
PlaceboOTHER
Sponsors & collaborators
Alliance for Clinical Trials in Oncologylead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Las VegasNevada, United States36DenverColorado, United States13HonoluluHawaii, United States11ColumbusOhio, United States8OmahaNebraska, United States6Des MoinesIowa, United States6Royal OakMichigan, United States6SeattleWashington, United States5CincinnatiOhio, United States5MinneapolisMinnesota, United States5GreenvilleSouth Carolina, United States4WichitaKansas, United States4
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03087708 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.